Hémoglobine glyquée
HbA1c
Révision par le Dr Laurence KnottDernière mise à jour par le Dr Colin Tidy, MRCGPDernière mise à jour le 17 janvier 2022
Répond aux besoins du patient lignes directrices éditoriales
- TéléchargerTélécharger
- Partager
Professionnels de la santé
Les articles de référence professionnelle sont destinés aux professionnels de la santé. Ils sont rédigés par des médecins britanniques et s'appuient sur les résultats de la recherche et sur les lignes directrices britanniques et européennes. L'article sur le diabète de type 2 vous sera peut-être plus utile, ou l'un de nos autres articles sur la santé.
Dans cet article :
Synonym: glycosylated haemoglobin
Poursuivre la lecture ci-dessous
What is an HbA1c test?
Glycated haemoglobin (HbA1c) laboratory tests are used to diagnose diabetes mellitus and to assess control in diabetes mellitus. For further information regarding HbA1c monitoring and targets, see the separate Management of Type 1 Diabetes and Type 2 Diabetes Treatment and Management articles.
Haemoglobin A1 and haemoglobin A1c
Chromatography of normal adult blood divides into two parts:
HbA (HbA0) 92-94%.
HbA1 (6-8%) where the B chain has an additional glucose group.
HbA1 itself consists of three different glycations, the HbA1c subgroup being the most useful, usually measured by isoelectric focusing or electrophoresis.
The glycation of haemoglobin occurs at a variable (non-linear rate) over time, during the whole lifespan of the red blood cell (RBC), which is normally 120 days. This means the relative proportion of glycated haemoglobin at any one time depends on the mean glucose level over the previous 120 days.
Normal levels (laboratory normal 'range') will differ depending on whether HbA1 or HbA1c is measured, and on the method used - use your laboratory's reference range (EDTA (FBC) bottle)1 .
HbA1c is usually a reliable indicator of diabetic control except in the following circumstances:
Situations where the average RBC lifespan is significantly less than 120 days will usually give rise to low HbA1c results because 50% of glycation occurs in days 90-120. Common causes include1 :
Increased red cell turnover: blood loss, haemolysis, haemoglobinopathies and red cell disorders, myelodysplastic disease.
Interference with the test (this depends on the method used: persistent fetal haemoglobin and haemoglobin variants, carbamylated haemoglobin (uraemic patients).
In patients who fluctuate between very high and very low levels - HbA1c readings can be misleading (the clinician should compare with extra information obtained from home capillary blood glucose tests).
HbA1c can be very useful in identifying patients who may be presenting an unrealistically good report of their home glucose tests.
Poursuivre la lecture ci-dessous
Normal ranges of HbA1c
HbA1c results in the UK have usually been aligned to the assay used in the Diabetes Control and Complications Trial (DCCT), expressed as a percentage (DCCT-HbA1c) - non-diabetic 'normal' range being 4-6%. Since 1st June 2009, HbA1c results in the UK have been standardised to the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) which will allow global comparison of results, with the equivalent normal non-diabetic range of IFCC-HbA1c being 20-42 mmol/mol2 .
Comparing DCCT-HbA1c and IFCC-HbA1c Results3
DCCT-HbA1c (%) | IFCC-HbA1c (mmol/mol) |
6.0 | 42 |
6.5 | 48 |
7.0 | 53 |
7.5 | 59 |
8.0 | 64 |
9.0 | 75 |
Other important points to consider
Any HbA1c target for the management of a person with diabetes should be individualised and agreed with the patient (considering comorbidity, life expectancy, hypoglycaemia frequency, etc).
Do not test more frequently than every three months - and avoid over-interpreting results. Look for trends rather than the difference in two consecutive results - test imprecision varies with the method used and is typically 3-4%.
Mean plasma glucose results are 10-15% higher than the equivalent HbA1c4 .
Poursuivre la lecture ci-dessous
Diagnosing diabetes5
Le diabète est généralement diagnostiqué par une HbA1c de 48 mmol/mol (6,5 %) ou plus. Si l'utilisation de l'HbA1c n'est pas appropriée (par exemple, chez les personnes souffrant d'une maladie rénale chronique en phase terminale), le diabète de type 2 est diagnostiqué par un taux de glucose plasmatique à jeun de 7,0 mmol/L ou plus.
Chez une personne asymptomatique, le diagnostic de diabète ne doit jamais reposer sur une seule anomalie de l'HbA1c ou de la glycémie à jeun ; au moins une autre anomalie de l'HbA1c ou de la glycémie est essentielle. Si les résultats du deuxième test sont normaux, il est prudent d'organiser un examen régulier de la personne.
Chez une personne symptomatique (soif, augmentation de la miction, infections récurrentes, perte de poids, somnolence et coma), le diabète peut être diagnostiqué avec plus de certitude sur la base d'un seul taux anormal d'HbA1c ou de glucose plasmatique à jeun (bien qu'un deuxième test puisse être prudent).
L'hyperglycémie sévère chez les personnes souffrant d'une infection aiguë, d'un traumatisme, d'un stress circulatoire ou autre peut être transitoire et ne doit pas être considérée comme un diagnostic de diabète.
Situations where HbA1c is not appropriate for diagnosis of diabetes include6 :
Les enfants et les jeunes.
Patients suspected of having type 1 diabetes.
Grossesse.
Patients with symptoms of diabetes for less than two months.
Patients at high diabetes risk who are acutely ill.
Patients taking medication that may cause rapid glucose rise - eg, steroids, antipsychotics.
Patients with acute pancreatic damage, including pancreatic surgery.
Presence of other factors that influence HbA1c and its measurement:
Erythropoiesis:
Increased HbA1c: iron deficiency, vitamin B12 deficiency, decreased erythropoiesis.
Decreased HbA1c: administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic liver disease.
Altered haemoglobin:
Genetic or chemical alterations in haemoglobin: haemoglobinopathies, HbF and methaemoglobin may increase or decrease HbA1c.
Glycation:
Increased HbA1c: alcohol dependency, chronic kidney disease.
Decreased HbA1c: aspirin, vitamin C and vitamin E, certain haemoglobinopathies.
Erythrocyte destruction:
Increased HbA1c: increased erythrocyte lifespan - eg, splenectomy.
Decreased HbA1c: decreased erythrocyte lifespan - eg, haemoglobinopathies, splenomegaly, rheumatoid arthritis or drugs such as antiretrovirals, ribavirin and dapsone.
Other factors:
Increased HbA1c: hyperbilirubinaemia, alcohol dependency, large doses of aspirin, chronic opiate use.
Variable HbA1c: haemoglobinopathies.
Decreased HbA1c: hypertriglyceridaemia.
HbA1c monitoring for diabetes7 8
For people with type 1 diabetes, the National Institute for Health and Care Excellence (NICE) recommends:
HbA1c levels every three to six months in adults with type 1 diabetes.
Consider measuring HbA1c levels more often in adults with type 1 diabetes if their blood glucose control is suspected to be changing rapidly; for example, if their HbA1c level has risen unexpectedly above a previously sustained target.
For adults with type 2 diabetes, NICE recommends:
Three-monthly to six-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy.
Six-monthly intervals once the HbA1c level and blood glucose-lowering therapy are stable.
Si la surveillance de l'HbA1c n'est pas valable en raison d'une perturbation du renouvellement des érythrocytes ou d'un type d'hémoglobine anormal, estimer les tendances du contrôle de la glycémie à l'aide de l'une des méthodes suivantes :
Estimation de la fructosamine.
Quality-controlled blood glucose profiles.
Estimation de l'hémoglobine glyquée totale (si hémoglobines anormales).
Fructosamine
Fructosamine is the glycated fraction of all plasma proteins (predominantly albumin) but considered less accurate because of the numerous factors affecting the half-lives of the many components. It generally reflects average glucose in the previous two weeks. If available, it may be useful in situations where there is reduced red cell survival time9 .
Autres lectures et références
- Reynolds TM, Smellie WS, Twomey PJ; Glycated haemoglobin (HbA1c) monitoring. BMJ. 2006 Sep 16;333(7568):586-8.
- Weykamp C; HbA1c: a review of analytical and clinical aspects. Ann Lab Med. 2013 Nov;33(6):393-400. doi: 10.3343/alm.2013.33.6.393. Epub 2013 Oct 17.
- Glucose testingDiabetes UK
- Rohlfing CL, Wiedmeyer HM, Little RR, et al; Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002 Feb;25(2):275-8.
- Utilisation de l'hémoglobine glyquée (HbA1c) dans le diagnostic du diabète sucréOrganisation mondiale de la santé, 2011
- John WG; Use of HbA1c in the diagnosis of diabetes. Diabetic Medicine, Volume 29, Issue 11, pages 1350–1357, November 2012
- Diabète de type 1 chez l'adulte : diagnostic et prise en chargeNICE Guidelines (août 2015 - dernière mise à jour août 2022)
- Diabète de type 2 chez l'adulte : prise en chargeNICE Guidance (décembre 2015 - dernière mise à jour juin 2022)
- Ribeiro RT, Macedo MP, Raposo JF; HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions. Curr Diabetes Rev. 2016;12(1):14-9. doi: 10.2174/1573399811666150701143112.
Poursuivre la lecture ci-dessous
Historique de l'article
Les informations contenues dans cette page sont rédigées et évaluées par des cliniciens qualifiés.
Date de la prochaine révision : 16 janvier 2027
17 Jan 2022 | Dernière version

Demandez, partagez, connectez-vous.
Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets liés à la santé.

Vous ne vous sentez pas bien ?
Évaluez gratuitement vos symptômes en ligne